DYSLIPIDEMIA

Question 1

REDUCE-IT trial full name

Answer 1

Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (REDUCE-IT)

Question 2

Design of the REDUCE-IT trial

Answer 2

REDUCE-IT was a phase 3b randomized, double-blind, placebo-controlled trial comparing icosapent ethyl (2 g twice daily with food [total daily dose, 4 g]) with a placebo that contains mineral oil to mimic the color and consistency of icosapent ethyl

Question 3

REDUCE-IT trial conclusion

Answer 3

Among patients with elevated triglyceride levels despite the use of statins, the risk of ischemic events, including cardiovascular death, was significantly lower among those who received 2 g of icosapent ethyl twice daily than among those who received placebo